Pfizer and BioNTech said they needed more data “because rates of infection and illness remain high in children of this age” due to the omicron variant.
Mass. General doc on Pfizer’s COVID-19 vaccine FDA application delay
Pfizer and BioNTech said they needed more data “because rates of infection and illness remain high in children of this age” due to the omicron variant.